In a preclinical study, a mouse surrogate antibody that targeted the GARP/LTGF-β1 complex improved anti-tumor effects in a combination setting with an anti-mouse programmed cell death protein 1 (PD-1) antibody when compared with the anti–PD-1 treatment alone. Here, LRRC32 is linked to neoplasm.